⌕
Supernus · SUPN · Nasdaq
Tenet 53 · Mixed
Compare
$29.04+0.73%At closeTenet 53 · Mixed
$29.04+0.21 (+0.73%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Supernus (SUPN) Stock

Supernus (SUPN) closed at $29.04 on Nov 17, 2026; its Tenet Score is 53 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

19 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$29.04
Nov 17, 2026
Market cap
$3.4B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
7.8×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
25.92 – 59.68
low → high · as of close, Nov 16, 2026
Tenet Score
53/100
Mixed · 340 Healthcare peers

Industry: Drugs

Supernus Inc. scores 53/100. Mixed. Strongest on value, financial health is the soft spot, trading at 8× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
53/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
73
Quality
60
Health
35
Growth
43

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueBQualityCHealthDGrowthDMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
2.5×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
21.1%
fiscal 2025, before interest and tax
Net margin
32.8%
TTM through Sep 30, 2026
Current ratio
0.61
Sep 30, 2026 balance sheet
Net debt / EBITDA
0.3×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Supernus Inc.

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Au…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 89 US ETFs · top wrappers by weightSee all ETFs holding SUPN →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Supernus in?

Supernus is in the Healthcare sector and the Drugs industry.

What is Supernus' Tenet Score?

Supernus' Tenet Score is 53 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.